Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDBioNexus Gene Lab Corp Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2025 | Q3 2025 | N/A | -$0.39 | N/A | N/A | $2.54 M |
| 08/18/2025 | Q2 2025 | N/A | -$0.34 | N/A | N/A | $2.26 M |
| 05/15/2025 | Q1 2025 | N/A | -$0.35 | N/A | N/A | $2.14 M |
| 04/15/2025 | Q4 2024 | N/A | -$0.19 | N/A | N/A | $2.52 M |
| 11/15/2024 | Q3 2024 | N/A | -$0.75 | N/A | N/A | $2.63 M |
| 08/14/2024 | Q2 2024 | N/A | $0.11 | N/A | N/A | $1.97 M |
| 05/15/2024 | Q1 2024 | N/A | -$0.06 | N/A | N/A | $2.38 M |
| 04/16/2024 | Q4 2023 | N/A | $0.17 | N/A | N/A | $2.27 M |
| 11/20/2023 | Q3 2023 | N/A | -$1.56 | N/A | N/A | $2.55 M |
| 05/31/2024 | Q2 2023 | N/A | -$0.02 | N/A | N/A | $2.57 M |
| 05/31/2024 | Q1 2023 | N/A | -$0.00 | N/A | N/A | $2.38 M |
| 05/31/2024 | Q4 2022 | N/A | -$0.01 | N/A | N/A | $2.84 M |
| 11/14/2022 | Q3 2022 | N/A | -$0.01 | N/A | N/A | $2.58 M |
| 08/15/2022 | Q2 2022 | N/A | -$0.01 | N/A | N/A | $2.49 M |
| 05/16/2022 | Q1 2022 | N/A | $0.00 | N/A | N/A | $3.03 M |
| 04/06/2022 | Q4 2021 | N/A | $0.01 | N/A | N/A | $3.25 M |
| 11/15/2021 | Q3 2021 | N/A | $0.02 | N/A | N/A | $3.58 M |
| 08/12/2021 | Q2 2021 | N/A | $0.00 | N/A | N/A | $3.09 M |
| 05/18/2021 | Q1 2021 | N/A | $0.02 | N/A | N/A | $3.45 M |
| 03/30/2021 | Q4 2020 | N/A | -$0.02 | N/A | N/A | $11.36 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
BioNexus Gene Lab Corp Earnings: FAQ's
The conference call for BioNexus Gene Lab Corp's latest earnings report can be listened to online.
The conference call transcript for BioNexus Gene Lab Corp's latest earnings report can be read online.
BioNexus Gene Lab Corp (:BGLC) has a recorded annual revenue of $9.51 M.
BioNexus Gene Lab Corp (:BGLC) has a recorded net income of $-1,598,342.BioNexus Gene Lab Corp has generated $-0.9 earnings per share over the last four quarters.
BioNexus Gene Lab Corp (:BGLC) has a price-to-earnings ratio of -1.78 and price/earnings-to-growth ratio is -0.08.